241 related articles for article (PubMed ID: 18277457)
1. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.
Tillman DK; Carroll MT
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s7-14. PubMed ID: 18277457
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report.
Rigel DS; Torres AM; Ely H
J Drugs Dermatol; 2008 Jan; 7(1 Suppl 1):s15-6. PubMed ID: 18277458
[TBL] [Abstract][Full Text] [Related]
3. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
4. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
Wu JK; Oh C; Strutton G; Siller G
Australas J Dermatol; 2006 Feb; 47(1):46-8. PubMed ID: 16405483
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma.
Spencer JM
Dermatol Surg; 2006 Jan; 32(1):63-9. PubMed ID: 16393600
[TBL] [Abstract][Full Text] [Related]
6. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
7. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
8. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
10. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
11. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
Garcia-Martin E; Idoipe M; Gil LM; Pueyo V; Alfaro J; Pablo LE; Zubiri ML; Fernandez J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):373-9. PubMed ID: 20698800
[TBL] [Abstract][Full Text] [Related]
13. Current modalities and new advances in the treatment of basal cell carcinoma.
Ceilley RI; Del Rosso JQ
Int J Dermatol; 2006 May; 45(5):489-98. PubMed ID: 16700779
[TBL] [Abstract][Full Text] [Related]
14. Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
Warshauer E; Warshauer BL
J Drugs Dermatol; 2008 May; 7(5):447-51. PubMed ID: 18505136
[TBL] [Abstract][Full Text] [Related]
15. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial.
Sinx KAE; Nelemans PJ; Kelleners-Smeets NWJ; Winnepenninckx VJL; Arits AHMM; Mosterd K
J Am Acad Dermatol; 2020 Aug; 83(2):469-476. PubMed ID: 32320773
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
17. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases.
Thissen MR; Kuijpers DI; Krekels GA
J Drugs Dermatol; 2006 May; 5(5):461-4. PubMed ID: 16703785
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nodular basal cell carcinoma with cryotherapy and reduced protocol of imiquimod.
Moutran R; Maatouk I; Stephan F; Tomb R
Cutis; 2012 Nov; 90(5):256-7. PubMed ID: 23270198
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
20. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
